{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:35:47Z","timestamp":1759941347033,"version":"3.44.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Microscopic polyangiitis (MPA) is an antineutrophil cytoplasmic antibody-associated vasculitis characterised by inflammation in small vessels. Avacopan, an oral C5a receptor inhibitor, has demonstrated efficacy in inducing and sustaining remission in MPA, with the added benefit of reducing glucocorticoid exposure and associated toxicities. Among adverse effects, liver injury is the most common, occurring in 16.7\u201340.9% of cases in the Japanese cohorts. Drug-induced hypersensitivity syndrome (DIHS) is a rare adverse effect caused by avacopan. We describe a case of a 77-year-old woman with MPA who was initiated on prednisolone 30\u00a0mg\/day and avacopan as the induction therapy. Disease activity of MPA improved with this induction therapy. However, 7\u00a0weeks after initiating avacopan, she developed significant liver dysfunction. Despite the discontinuation of avacopan, she subsequently presented with fever and a generalised rash, leading to a diagnosis of DIHS. Laboratory data revealed reactivation of human herpesvirus 6. Despite the discontinuation of avacopan, liver injury persisted, and liver biopsy findings were consistent with drug-induced hepatitis. Long-term hospitalisation was required for improvement in skin symptoms and liver function. This case highlights a rare but serious adverse event of avacopan in MPA. During avacopan therapy, it is necessary to monitor for delayed severe skin symptoms such as DIHS.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf054","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T12:42:27Z","timestamp":1755175347000},"source":"Crossref","is-referenced-by-count":1,"title":["Unexpected adverse event caused by avacopan: a case of drug-induced hypersensitivity syndrome in microscopic polyangiitis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0553-607X","authenticated-orcid":false,"given":"Hiroki","family":"Nibu","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Collagen Disease, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]},{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4305-2048","authenticated-orcid":false,"given":"Haruki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Collagen Disease, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]},{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-9501","authenticated-orcid":false,"given":"Hiroki","family":"Irie","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Konno","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-9226","authenticated-orcid":false,"given":"Yukiko","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Motoki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Tasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6538-1881","authenticated-orcid":false,"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8110-8261","authenticated-orcid":false,"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Collagen Disease, Fukushima Red Cross Hospital , Fukushima ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025090110371070700_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025090110371070700_ref2","doi-asserted-by":"crossref","first-page":"m421","DOI":"10.1136\/bmj.m421","article-title":"Management of ANCA associated vasculitis","volume":"368","author":"Wallace","year":"2020","journal-title":"BMJ"},{"key":"2025090110371070700_ref3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated Vasculitis","volume":"384","author":"DRW","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090110371070700_ref4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3899\/jrheum.2024-0340.C1","article-title":"Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"51","author":"Uchida","year":"2024","journal-title":"J Rheumatol"},{"key":"2025090110371070700_ref5","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025090110371070700_ref6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090110371070700_ref7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"2025090110371070700_ref8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijd.IJD_582_17","article-title":"Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature","volume":"63","author":"De","year":"2018","journal-title":"Indian J Dermatol"},{"key":"2025090110371070700_ref9","first-page":"58","article-title":"Chronic administration of oral trimethoprim-sulfamethoxazole for acne vulgaris","volume":"4","author":"McCarty","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025090110371070700_ref10","doi-asserted-by":"crossref","first-page":"1488483","DOI":"10.3389\/fphar.2024.1488483","article-title":"Literature review of the clinical features of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome (DRESS\/DIHS)","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025090110371070700_ref11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/mr\/roac027","article-title":"Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice: a two-centre study in Fukushima","volume":"33","author":"Yashiro-Furuya","year":"2023","journal-title":"Japan Mod Rheumatol"},{"key":"2025090110371070700_ref12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025090110371070700_ref13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5387\/fmedj.73.2_29","article-title":"Microscopic polyangiitis presenting as rapidly progressive glomerulonephritis treatment with the complement C5a receptor inhibitor, avacopan : three case report","volume":"73","author":"Sato","year":"2023","journal-title":"Fukushima Med J"},{"key":"2025090110371070700_ref14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13730-024-00910-1","article-title":"A case of renal limited myeloperoxidase anti-neutrophil cytoplasmic antibody-positive vasculitis treated with maintenance avacopan monotherapy","volume":"14","author":"Ubara","year":"2025","journal-title":"CEN Case Rep"},{"key":"2025090110371070700_ref15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2169\/internalmedicine.4389-24","article-title":"Effectiveness and safety of avacopan as a combination therapy with glucocorticoids or monotherapy in patients with microscopic polyangiitis","volume":"64","author":"Jubashi","year":"2025","journal-title":"Intern Med"},{"key":"2025090110371070700_ref16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41927-025-00456-4","article-title":"Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan","volume":"9","author":"Tagami","year":"2025","journal-title":"BMC Rheumatol"},{"key":"2025090110371070700_ref17","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090110371070700_ref18","doi-asserted-by":"crossref","first-page":"1001302","DOI":"10.37349\/emed.2025.1001302","article-title":"Vanishing bile duct syndrome in drug-induced liver injury: clinical and pathologic perspectives","volume":"6","author":"Sallapan","year":"2025","journal-title":"Explor Med"},{"key":"2025090110371070700_ref19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2133.2006.07332.x","article-title":"Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome","volume":"155","author":"Seishima","year":"2006","journal-title":"Br J Dermatol"},{"key":"2025090110371070700_ref20","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1386-6532(06)70019-1","article-title":"Human herpesvirus 6 reactivation and inflammatory cytokine production in patients with drug-induced hypersensitivity syndrome","volume":"37","author":"Yoshikawa","year":"2006","journal-title":"J Clin Virol"},{"key":"2025090110371070700_ref21","doi-asserted-by":"crossref","first-page":"113165","DOI":"10.1016\/j.intimp.2024.113165","article-title":"Complement component 5a receptor 1 and leukotriene B4 receptor 1 regulate neutrophil extracellular trap (NET) formation through Rap1a\/B-Raf\/ERK signaling pathway and their deficiency in term low birth weight newborns leads to deficient NETosis","volume":"142","author":"Das","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2025090110371070700_ref22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-immunol-042617-053245","article-title":"Complement and the regulation of T cell responses","volume":"36","author":"West","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"2025090110371070700_ref23","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.4049\/jimmunol.1401750","article-title":"The C5a anaphylatoxin receptor (C5aR1) protects against listeria monocytogenes infection by inhibiting type 1 IFN expression","volume":"193","author":"Calame","year":"2014","journal-title":"J Immunol"},{"key":"2025090110371070700_ref24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00535-020-01662-2","article-title":"Activation of interferon regulatory factor 7 in plasmacytoid dendritic cells promotes experimental autoimmune pancreatitis","volume":"55","author":"Minaga","year":"2020","journal-title":"J Gastroenterol"},{"key":"2025090110371070700_ref25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.alit.2021.12.002","article-title":"Drug allergy and non-HIV immune reconstitution inflammatory syndrome","volume":"71","author":"Sueki","year":"2022","journal-title":"Allergol Int"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf054\/64044170\/rxaf054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf054\/64044170\/rxaf054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf054\/64044170\/rxaf054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:37:20Z","timestamp":1756737440000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf054\/8234323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf054","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf054"}}